A provider briefing on Exxua (Gepirone) availability in 2026: distribution model, prescribing implications, insurance hurdles, and tools to help patients.
Exxua (Gepirone) represents the first new class of oral antidepressant in decades — a selective 5-HT1A receptor partial agonist approved for major depressive disorder in adults. For clinicians who have long needed an antidepressant without the burden of sexual dysfunction or significant weight gain, Exxua is a welcome addition to the pharmacologic toolbox.
However, prescribing Exxua in early 2026 comes with practical challenges. This briefing covers what you need to know about availability, distribution, insurance considerations, and tools to support your patients.
Understanding the timeline helps contextualize the current situation:
The 27-month gap between FDA approval and commercial availability is unusual but reflects the need for a commercialization partner. Fabre-Kramer developed the drug but lacked the commercial infrastructure to launch it independently.
Exxua is a selective partial agonist of the 5-HT1A receptor with a distinct profile from SSRIs and SNRIs:
For a comprehensive clinical review, see our detailed article on Exxua's mechanism of action.
Exxua is not in a formal FDA drug shortage. However, real-world availability is limited by its distribution model:
Practically, this means your patients may call multiple pharmacies before finding one that carries Exxua. Setting expectations at the point of prescribing can reduce frustration.
Exxua's retail cash price is approximately $1,500-$1,800/month for 30 tablets, depending on strength. No generic is available (NCE exclusivity through September 2028).
Most commercial and Medicare Part D plans are still evaluating Exxua for formulary inclusion. Current trends:
Aytu offers the RxConnect program, which provides:
Several factors suggest Exxua availability will improve throughout 2026:
For providers managing patients who need immediate treatment and can't access Exxua, our guide on alternatives to Exxua covers the most relevant options, including Buspirone augmentation, Bupropion, Auvelity, and Vortioxetine.
Exxua fills a genuine clinical need — an oral antidepressant for MDD that avoids the sexual dysfunction and weight gain that drive non-adherence to SSRIs and SNRIs. The current availability challenges are a function of its recent launch and specialty distribution model, not a supply shortage.
Providers can best support their patients by setting realistic expectations about pharmacy availability, leveraging the Aytu RxConnect network and PA support tools, and using Medfinder for Providers to locate stock. As distribution matures throughout 2026, prescribing Exxua should become increasingly straightforward.
For a step-by-step workflow guide, see our companion post: How to help your patients find Exxua in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
